JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

Strona główna・Stock List・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Closed

SectorHealthcare

4.84 4.09

Buy Sell

Overview

Share price change

24h

Current

Min

4.59

Max

4.87

Key metrics
By Trading Economics
Income	21M 61M
Sales	-74M 48M
P/E Sector Avg	28.688 67.147
Profit margin	128.703
Employees	100
EBITDA	-68M 8.8M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+117.86% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	146M 756M
Previous open	0.75
Previous close	4.84

News Sentiment

By Acuity

50%

180 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

N/A / 0.9337 Support & Resistance

Ironwood Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 maj 2026, 23:43 UTC

Major News Events

New Zealand's Unemployment Rate Falls in 1Q

5 maj 2026, 23:20 UTC

Hot Stocks

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 maj 2026, 21:48 UTC

Earnings

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 maj 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 maj 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 maj 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 maj 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 maj 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 maj 2026, 22:08 UTC

Earnings

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 maj 2026, 22:07 UTC

Earnings

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Rev $1.2B >PAAS

5 maj 2026, 21:42 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:38 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:30 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:29 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:26 UTC

Earnings

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q EPS 39c >ALC.EB

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 maj 2026, 21:24 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:18 UTC

Earnings

Mistras Backs 2026 Rev $730M-$750M >MG

5 maj 2026, 21:17 UTC

Earnings

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 maj 2026, 21:15 UTC

Earnings

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 maj 2026, 21:12 UTC

Earnings

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 maj 2026, 21:11 UTC

Earnings

SSR Mining 1Q Rev $581.8M >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q EPS $1.16 >SSRM

5 maj 2026, 21:08 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:01 UTC

Earnings

Intact Financial 1Q EPS C$4.12 >IFC.T

5 maj 2026, 21:01 UTC

Hot Stocks

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Comparison

Price change

Ironwood Pharmaceuticals Inc Forecast

Price Target

By TipRanks

117.86% upside

12 Months Forecast

Average 10 USD 117.86%

High 10 USD

Low 10 USD

Based on 2 Wall Street analysts offering 12 month price targets forIronwood Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Ironwood Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 0.9337Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

All events are bearish.

Sentiment

By Acuity

180 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.